Triamcinolone Acetonide Cream USP, 0.1%, packaged in a) 15 grams tubes, NDC 52565-056-15; b) 30 grams tubes, NDC 52565-056-30; c) 80 grams tubes, NDC 52565-056-80, d) 1 lb (454 g) jars, NDC 52565-056-26; Rx Only, Teligent Pharma, Inc., Buena, New Jersey 08310.

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Recall #: D-0697-2022
Affected scope: 721,225 tubes; 90,893 jars
Initiated: March 15, 2022

Compiled from official public sources by the publisher. · Updated September 2026

Verify with FDA Drug →

View my saved recalls

Teligent Pharma, Inc. recalled Triamcinolone Acetonide Cream USP, 0.1%, packaged in a) 15 grams tubes, NDC 52565-056-15;… - a moderate-severity action.

Triamcinolone Acetonide Cream USP, 0.1%, packaged in a) 15 grams tubes, NDC 52565-056-15;… was recalled by Teligent Pharma, Inc. in March 30, 2022. Reason: cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stabilit…. Check the official notice for the remedy. Verify recall #D-0697-2022 with the FDA Drug before acting.

The recall

Teligent Pharma, Inc. issued this moderate-severity FDA Drug recall-cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stabilit….

Moderate
severity level: Class II
classification: March 30, 2022
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0697-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 3 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Triamcinolone Acetonide Cream USP, 0.1%, packaged in a) 15 grams tubes, NDC 52565-056-15; b) 30 grams tubes, NDC 52565-056-30; c) 80 grams tubes, NDC 52565-056-80, d) 1 lb (454 g) jars, NDC 52565-056-26; Rx Only, Teligent Pharma, Inc., Buena, New Jersey 08310.

Reason for recall

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Moderate (Class II)
Status	Terminated
Recall number	D-0697-2022
Date reported	March 30, 2022
Date initiated	March 15, 2022
Recalling firm	Teligent Pharma, Inc.
Firm location	Buena, NJ
Affected scope	721,225 tubes; 90,893 jars
Distribution	Nationwide in the USA and Puerto Rico

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0697-2022) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on March 30, 2022. Severity: Moderate. Recall number: D-0697-2022.

Where was the recalled product distributed? ▼

Distribution: Nationwide in the USA and Puerto Rico.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Moderate), closest by report date among other firms and states.

Norepinephrine Bitartrate Injection 4mg p… 2022-03-30 Norepinephrine Bitartrate Injection 16 mg… 2022-03-30 Norepinephrine Bitartrate Injection 8 mg … 2022-03-30 Phenylephrine HCl Injection 40 mg per 250… 2022-03-30

Similar Cosmetics & Personal Care · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Clotrimazole and Betamethasone Dipropiona… 2022-04-06 Bob Evan's Sour Cream & Chive Mashed Pota… 2022-03-23 Econazole Nitrate Cream, 1%, Generic for … 2022-04-20 Lidocaine Prilocaine Cream USP, 2.5%/2.5%… 2022-05-11

Compare this recall with Ice Pop, D'Dioses Cookies Cream, 1 Bar (81.7 g), with UPC 7… → · All Cosmetics & Personal Care recalls

This recall: FDA Drug, reported March 30, 2022. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026